Keeping Track: AbbVie Is First With HCV Genotype 4 NDA, Merck Files Keytruda For NSCLC
Executive Summary
Weekly column reviews the latest drug development news from our FDA Performance Tracker. This week: updates on AbbVie's HCV franchise, Merck's Keytruda and a PD-L1 companion diagnostic, and botulinum toxins from Merz and Actavis.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.